The pharmacokinetics and pharmacodynamics of two multiple-dose regimens of piperacillin-
tazobactam (3.375 g every 6 h and 4.5 g every 8 h) were evaluated at steady state for 12 …

In the present study 24 hospitalized patients requiring empirical antibiotic treatment were
randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination …

Study Objective. To compare the pharmacokinetic and pharmacodynamic profiles of two
dosing regimens for piperacillin‐tazobactam against commonly encountered pathogens …

The objective of this study was to evaluate the steady-state pharmacokinetics and
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …

Background: Although intermittent bolus dosing is currently the standard of practice for many
antimicrobial agents, beta-lactams exhibit time-dependent bacterial killing. Maximizing the …

A multiple-dose, open-labelled, randomized, two period crossover human volunteer study
was performed (i) to describe the pharmacokinetic profile and safety profile of piperacillin …

When piperacillin/tazobactam has been used to treat hospitalized patients with serious
infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has …

Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-
lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin …

The pharmacodynamics of dosage regimens of piperacillin alone or in combination with
tazobactam against piperacillin-resistant or-susceptible bacteria were studied in an in vitro …

ABSTRACT A population pharmacokinetic (PK) analysis was conducted to determine if
piperacillin and tazobactam exhibited linear or nonlinear PKs and if incremental changes in …